ReviewAdvances in therapy2020
Burden of Community-Acquired Pneumonia and Unmet Clinical Needs.
Review in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
137 citing papers in PubMed, 5 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- The risk of cardiovascular, cerebrovascular and thromboembolic events after community-acquired pneumonia among adults: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Efficacy and safety of vitamin C supplementation in the treatment of community-acquired pneumonia: a systematic review and meta-analysis with trial sequential analysis.Scientific reports · 2024Pooled it
- Chest physiotherapy for pneumonia in adults.The Cochrane database of systematic reviews · 2022Pooled it
- Comparative efficacy of azithromycin versus clarithromycin in combination with beta-lactams to treat community-acquired pneumonia in hospitalized patients: a systematic review.The Journal of international medical research · 2021Pooled it
- Predictive roles of D-dimer for mortality of patients with community-acquired pneumonia: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Pooled it
- Immunogenicity and safety of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults ≥18 years of age in India: A phase 3 single-arm trial.Human vaccines & immunotherapeutics · 2026Trial
- Traditional Chinese Medicine treatment with syndrome differentiation for patients with severe community-acquired pneumonia: a multicenter, randomized, placebo-controlled trial.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Trial
- Trial
- Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.Critical care (London, England) · 2023Trial
- Pneumococcal serotype distribution and diagnostic yield of serotype-specific urinary antigen detection in adults with CAP in Switzerland, 2016-2021: a prospective cohort study.BMC infectious diseases · 2026Article
- Disease burden of viral respiratory infections in people with intellectual disabilities: a scoping review.BMJ open respiratory research · 2026Article
- Low CT-Derived Thoracic Muscle Area and Composite Weaning Failure in Mechanically Ventilated ICU Patients with Pneumonia: An Exploratory Analysis by Age Group.Journal of clinical medicine · 2026Article
- Observational
- Article
- Article
- Early Machine Learning-Based Identification of Hospitalized Patients at Low Risk of Respiratory Deterioration or Mortality in Community-Acquired Pneumonia: External Validation of a Multivariable Model.Infectious disease reports · 2026Article
- Clinical characteristics and risk factors associated with mortality in patients with severe community-acquired pneumonia in the intensive care unit.Journal of thoracic disease · 2026Article
- Pharmacological evaluation of selected medicinal plant extracts against multidrug-resistant Klebsiella pneumoniae: implications for inflammation-associated respiratory infections.Inflammopharmacology · 2026Article
- Erector spinae muscle characteristics predict 90-day survival in elderly pneumonia patients.Scientific reports · 2026Observational
- METTL14/IGF2BP1 mInfection and immunity · 2026Article
77 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) is the leading cause of death among infectious diseases and an important health problem, having considerable implications for healthcare systems worldwide. Despite important advances in prevention through vaccines, new rapid diagnostic tests and antibiotics, CAP management still has significant drawbacks. Mortality remains very high in severely ill patients presenting with respiratory failure or shock but is also high in the elderly. Even after a CAP episode, higher risk of death remains during a long period, a risk mainly driven by inflammation and patient-related co-morbidities. CAP microbiology has been altered by new molecular diagnostic tests that have turned viruses into the most identified pathogens, notwithstanding uncertainties about the specific role of each virus in CAP pathogenesis. Pneumococcal vaccines also impacted CAP etiology and thus had changed Streptococcus pneumoniae circulating serotypes. Pathogens from specific regions should also be kept in mind when treating CAP. New antibiotics for CAP treatment were not tested in severely ill patients and focused on multidrug-resistant pathogens that are unrelated to CAP, limiting their general use and indications for intensive care unit (ICU) patients. Similarly, CAP management could be personalized through the use of adjunctive therapies that showed outcome improvements in particular patient groups. Although pneumococcal vaccination was only convincingly shown to reduce invasive pneumococcal disease, with a less significant effect in pneumococcal CAP, it remains the best therapeutic intervention to prevent bacterial CAP. Further research in CAP is needed to reduce its population impact and improve individual outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.